Viz.ai to Collaborate With Guardant Health to Improve Lung Cancer Detection, Diagnosis, and Treatment
Viz.ai and Guardant Health (GH) announced a proposed collaboration to improve lung cancer care through the integration of AI and genomic insights. The partnership aims to address the critical issue that approximately 40% of lung cancer patients do not receive guideline-directed medical therapy.
The collaboration will focus on facilitating timely biomarker testing using Guardant360® CDx liquid biopsy, accelerating precision diagnosis and treatment selection. Viz.ai's platform, currently implemented in 1,700 hospitals, uses machine learning to analyze imaging data, EHR, and other tests to provide real-time insights and automated assessments.
This initiative aims to tackle delays in diagnosis, testing, and treatment that can lead to cancer progression and higher mortality rates. The partnership combines Viz.ai's AI-powered disease detection capabilities with Guardant Health's precision oncology expertise to streamline the patient journey and improve outcomes.
Viz.ai e Guardant Health (GH) hanno annunciato una proposta di collaborazione per migliorare le cure contro il cancro ai polmoni attraverso l'integrazione di IA e approfondimenti genomici. L'obiettivo della partnership è affrontare la questione critica che circa il 40% dei pazienti con cancro ai polmoni non riceve terapie mediche secondo le linee guida.
La collaborazione si concentrerà sul facilitare test tempestivi dei biomarcatori utilizzando la biopsia liquida Guardant360® CDx, accelerando la diagnosi precisa e la selezione del trattamento. La piattaforma di Viz.ai, attualmente implementata in 1.700 ospedali, utilizza l'apprendimento automatico per analizzare dati di imaging, EHR e altri test per fornire approfondimenti in tempo reale e valutazioni automatizzate.
Questa iniziativa mira ad affrontare i ritardi nella diagnosi, nei test e nei trattamenti che possono portare a una progressione del cancro e a tassi di mortalità più elevati. La partnership combina le capacità di rilevazione delle malattie potenziate dall'IA di Viz.ai con l'esperienza in oncologia di precisione di Guardant Health per semplificare il percorso del paziente e migliorare i risultati.
Viz.ai y Guardant Health (GH) anunciaron una colaboración propuesta para mejorar la atención del cáncer de pulmón a través de la integración de IA y conocimientos genómicos. La asociación tiene como objetivo abordar el problema crítico de que aproximadamente el 40% de los pacientes con cáncer de pulmón no recibe terapia médica guiada por las directrices.
La colaboración se enfocará en facilitar pruebas de biomarcadores oportunas utilizando la biopsia líquida Guardant360® CDx, acelerando así el diagnóstico preciso y la selección de tratamientos. La plataforma de Viz.ai, actualmente implementada en 1,700 hospitales, utiliza el aprendizaje automático para analizar datos de imagen, EHR y otras pruebas para proporcionar información en tiempo real y evaluaciones automatizadas.
Esta iniciativa tiene como objetivo abordar los retrasos en el diagnóstico, las pruebas y el tratamiento que pueden llevar a la progresión del cáncer y a tasas de mortalidad más altas. La asociación combina las capacidades de detección de enfermedades impulsadas por IA de Viz.ai con la experiencia en oncología de precisión de Guardant Health para simplificar el recorrido del paciente y mejorar los resultados.
Viz.ai와 Guardant Health (GH)는 AI와 유전자 정보를 통합하여 폐암 치료를 개선하기 위한 협업을 발표했습니다. 이번 파트너십의 목표는 약 40%의 폐암 환자가 지침에 따른 의학적 치료를 받지 않는 중요한 문제를 해결하는 것입니다.
협업은 Guardant360® CDx 액체 생검을 사용하여 적시 바이오 마커 테스트를 촉진하고 정밀 진단 및 치료 선택을 가속화하는 데 중점을 둘 것입니다. 현재 1,700개 병원에서 구현된 Viz.ai의 플랫폼은 머신러닝을 사용하여 이미징 데이터, 전자 건강 기록(EHR) 및 기타 테스트를 분석하여 실시간 통찰력과 자동 평가를 제공합니다.
이 이니셔티브는 진단, 테스트 및 치료의 지연으로 인해 발생할 수 있는 암 진행 및 높은 사망률 문제를 해결하는 것을 목표로 합니다. 이번 파트너십은 Viz.ai의 AI 기반 질병 감지 기능과 Guardant Health의 정밀 종양학 전문 지식을 결합하여 환자 여정을 간소화하고 결과를 개선합니다.
Viz.ai et Guardant Health (GH) ont annoncé une collaboration proposée pour améliorer les soins du cancer du poumon grâce à l'intégration de l'IA et des informations génomiques. L'objectif de ce partenariat est de s'attaquer à la question critique selon laquelle environ 40% des patients atteints de cancer du poumon ne reçoivent pas de thérapie médicale conforme aux directives.
La collaboration se concentrera sur la facilitation de tests de biomarqueurs en temps utile à l'aide de la biopsie liquide Guardant360® CDx, accélérant ainsi le diagnostic précis et la sélection du traitement. La plateforme de Viz.ai, actuellement mise en œuvre dans 1 700 hôpitaux, utilise l'apprentissage automatique pour analyser les données d'imagerie, les dossiers de santé électroniques (DSE) et d'autres tests afin de fournir des informations en temps réel et des évaluations automatisées.
Cette initiative vise à lutter contre les retards dans le diagnostic, les tests et les traitements qui peuvent entraîner une progression du cancer et des taux de mortalité plus élevés. Ce partenariat combine les capacités de détection des maladies propulsées par l'IA de Viz.ai avec l'expertise en oncologie de précision de Guardant Health afin de simplifier le parcours des patients et d'améliorer les résultats.
Viz.ai und Guardant Health (GH) haben eine vorgeschlagene Zusammenarbeit zur Verbesserung der Lungenkrebspflege durch die Integration von KI und genomischen Erkenntnissen angekündigt. Die Partnerschaft zielt darauf ab, das kritische Problem anzugehen, dass ungefähr 40% der Lungenkrebspatienten keine richtliniengerechte medizinische Therapie erhalten.
Die Zusammenarbeit wird sich darauf konzentrieren, zeitnahe Biomarkertests unter Verwendung von Guardant360® CDx Flüssigbiopsie zu erleichtern, um die präzise Diagnosestellung und Behandlungsauswahl zu beschleunigen. Die Plattform von Viz.ai, die derzeit in 1.700 Krankenhäusern implementiert ist, nutzt maschinelles Lernen, um Bilddaten, elektronische Patientenakten (EHR) und andere Tests zu analysieren und Echtzeiteinblicke sowie automatisierte Bewertungen bereitzustellen.
Diese Initiative zielt darauf ab, Verzögerungen bei Diagnosen, Tests und Behandlungen zu bekämpfen, die zu einer Krebsprogression und höheren Sterblichkeitsraten führen können. Die Partnerschaft kombiniert die KI-gesteuerten Krankheitsdetektionsfähigkeiten von Viz.ai mit der Expertise der präzisen Onkologie von Guardant Health, um den Patientenweg zu optimieren und die Ergebnisse zu verbessern.
- Strategic collaboration with Viz.ai expands GH's market reach to 1,700 hospitals
- Integration of Guardant360® CDx liquid biopsy into AI platform enhances product adoption
- Addresses large untapped market with 40% of patients not receiving proper therapy
- None.
Insights
The proposed collaboration between Viz.ai and Guardant Health represents a strategic move in the $31.6 billion global lung cancer diagnostics market. The integration of AI-powered detection with liquid biopsy technology addresses a critical 40% gap in guideline-directed medical therapy for lung cancer patients. For Guardant Health, this partnership could significantly expand the adoption of their Guardant360 CDx liquid biopsy across Viz.ai's network of 1,700 hospitals.
Think of this as combining a highly sensitive radar system (Viz.ai's AI) with precision targeting capabilities (Guardant's genomic testing) - together they create a more powerful system for detecting and treating lung cancer. For investors, this collaboration could accelerate Guardant Health's market penetration and revenue growth in the lung cancer segment, while also reducing customer acquisition costs through Viz.ai's established hospital network.
The technical synergy between these platforms is particularly compelling. Viz.ai's machine learning algorithms analyzing real-time imaging and EHR data, combined with Guardant's liquid biopsy capabilities, creates an end-to-end solution for precision oncology. This integration could significantly reduce the time from initial detection to treatment initiation, currently a major bottleneck in lung cancer care.
In simpler terms, imagine having a smart assistant that not only spots potential cancer cases automatically but also immediately orders the right genetic tests and helps doctors choose the best treatment - all happening much faster than traditional methods. This automation and streamlining of the diagnostic workflow could lead to substantial cost savings for healthcare providers while improving patient outcomes.
Proposed collaboration aims to integrate cutting-edge AI and genomic insights to advance guideline-directed medical therapy
“This collaboration represents a promising step forward in the fight against lung cancer and reflects our commitment to expanding Viz.ai’s impact in oncology,” said Dr. Chris Mansi, CEO and co-founder at Viz.ai. “Together, we have the opportunity to harness the power of AI and genomics to ensure patients receive timely, personalized, and effective care.”
Nearly
The Viz.ai One platform leverages machine learning algorithms to analyze data from imaging, the EHR and other tests and deliver real-time, actionable insights and automated assessments to accelerate diagnosis and treatment. Viz.ai acts as a safety net in 1,700 hospitals to automatically identify patients with disease and direct them to the right specialist and the right treatment.
Learn more about Viz.ai’s commitment to lung cancer here.
About Viz.ai
Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care across 1,700 hospitals and health systems in the
1 |
|
Blom EF, Ten Haaf K, Arenberg DA, de Koning HJ. Disparities in Receiving Guideline-Concordant Treatment for Lung Cancer in |
View source version on businesswire.com: https://www.businesswire.com/news/home/20250114341057/en/
Media Contact
Brendi Bluitt
brendi.bluitt@finnpartners.com
Source: Viz.ai
FAQ
What is the purpose of the Viz.ai and Guardant Health (GH) collaboration?
How many hospitals currently use Viz.ai's platform that will integrate with Guardant Health (GH)?
What percentage of lung cancer patients will the GH and Viz.ai collaboration target?
What specific Guardant Health (GH) product will be integrated into the Viz.ai platform?
